WASHINGTON, DC — While Incyte and the founders of Flexus scrap in court over who owns the IDO1 technology that Bristol-Myers Squibb $BMY bought in a $1.25 billion deal a couple of years ago, Bristol-Myers is ready to start putting the early-stage data from a combination study with Opdivo on display.
Today at the SITC meeting, investigators say their ongoing Phase I/II study of the checkpoint drug Opdivo plus BMS-986205 produced some varying positive results for heavily pre-treated bladder (25 cases) and cervical cancer patients (22 patients).
— In the bladder cancer cohort, the objective response rate and disease control rate were 32% and 44%, respectively.
— In the cervical cancer cohort, the ORR was 14% and DCR was 64%.
PD-L1 expression mattered. Zeroing in on patients who express PD-L1 more than 1%, ORR was 46% and 25% in the bladder and cervical cancer groups, respectively, while for patients who express PD-L1 less than 1%, ORR was 22% in the bladder cancer cohort with no responses observed in cervical cancer patients.
In a court case filed in Delaware, Incyte claimed that Jordan Fridman, a scientist in its ranks, had systematically lifted its IDO1 secrets before making his way to Flexus, which subsequently accepted a jaw-dropping buyout offer from Bristol-Myers. The lawsuit filed against Flexus founders Terry Rosen and Juan Jean seeks more than a billion dollars in damages.
Incyte $INCY has the most advanced IDO1 in the clinic — epacadostat — and is clearly intent on defending its IP turf. Bristol-Myers, meanwhile, is placing a heavy emphasis on moving as fast as possible on the IDO1 front as it pushes ahead with its big checkpoint therapy and combos around it.
Bristol-Myers IDO development lead Mark Rutstein noted:
We are urgently pursuing transformative research to better understand tumor evasion mechanisms to help inform potential new treatment options for patients with advanced cancers. BMS-986205 has shown encouraging characteristics, including potent and selective inhibition of IDO1, as well as pharmacokinetic data that support once-daily dosing. We look forward to additional data from this study.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.Free Subscription